--- title: "How Investors Are Reacting To Zoetis (ZTS) Cut Guidance Flat Q2 Results And New FDA EUA" type: "News" locale: "en" url: "https://longbridge.com/en/news/296250302.md" description: "Zoetis reported flat Q2 sales and net income, while cutting full-year 2026 revenue and EPS guidance. The company secured an FDA EUA for Simparica Trio against screwworm and appointed Jay Saccaro as CFO/COO. Analysts note the guidance cut shifts focus to near-term execution and innovation-led growth, with competitive pressures posing risks to future earnings." datetime: "2026-08-18T15:39:24.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/296250302.md) - [en](https://longbridge.com/en/news/296250302.md) - [zh-HK](https://longbridge.com/zh-HK/news/296250302.md) generator: "portal-rs" --- # How Investors Are Reacting To Zoetis (ZTS) Cut Guidance Flat Q2 Results And New FDA EUA - Zoetis recently reported second-quarter 2026 results showing essentially flat year-on-year sales at US$2,468 million and slightly lower net income of US$691 million, alongside a full-year 2026 guidance cut to revenue of US$9.12–US$9.32 billion and diluted EPS of US$5.55–US$5.65. - Around the same time, Zoetis secured an FDA Emergency Use Authorization for Simparica Trio against New World screwworm in dogs and appointed experienced life sciences executive Jay Saccaro as both CFO and COO, reshaping its leadership and product toolkit amid a more challenging growth backdrop. - Next, we’ll examine how the lowered 2026 earnings guidance reshapes Zoetis’ investment narrative built around innovation-led growth and margin expansion. Find 53 companies with promising cash flow potential yet trading below their fair value. ## Zoetis Investment Narrative Recap To own Zoetis, you need to believe its leading animal health franchises and innovation engine can still justify a premium despite slower recent growth and a cut to 2026 earnings guidance. The lowered outlook makes near term execution the key catalyst, while the biggest risk is that competitive and demand pressures in core categories turn today’s muted growth into a more persistent earnings drag. The latest news does not fundamentally change that risk balance, but it puts more scrutiny on delivery. The most relevant update here is Zoetis’ sharp reduction in 2026 revenue and EPS guidance to US$9.12–US$9.32 billion and US$5.55–US$5.65. That reset reframes expectations around innovation led growth and margin expansion, and makes investors more sensitive to how quickly new products like Simparica Trio’s expanded EUA use and the OA pain portfolio can offset pressure elsewhere and support any future re rating in sentiment. But beneath Zoetis’ long track record, a less obvious risk that investors should be aware of is ... Read the full narrative on Zoetis (it's free!) Zoetis’ narrative projects $10.7 billion revenue and $3.1 billion earnings by 2029. This requires 3.9% yearly revenue growth and about a $0.4 billion earnings increase from $2.7 billion today. Uncover how Zoetis' forecasts yield a $114.76 fair value, a 57% upside to its current price. ## Exploring Other Perspectives ZTS 1-Year Stock Price Chart Some of the lowest ranked analysts were already assuming only about 3 percent annual revenue growth to roughly US$10.4 billion by 2029, and the latest guidance cut plus Simparica Trio’s EUA highlight why your view on regulatory and competitive risks could still shift meaningfully from here. Explore 10 other fair value estimates on Zoetis - why the stock might be worth just $80.00! ## The Verdict Is Yours Don't just follow the ticker - dig into the data and build a conviction that's truly your own. - A great starting point for your Zoetis research is our analysis highlighting 4 key rewards and 1 important warning sign that could impact your investment decision. - Our free Zoetis research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Zoetis' overall financial health at a glance. ## Ready For A Different Approach? Markets shift fast. These stocks won't stay hidden for long. Get the list while it matters: - Invest in the nuclear renaissance through our list of 93 elite nuclear energy infrastructure plays powering the global AI revolution. - The future of work is here. Discover the 37 top robotics and automation stocks leading the charge in AI-driven automation and industrial transformation. - Rare earth metals are the new gold rush. Find out which 28 stocks are leading the charge. *This article by Simply Wall St is general in nature. **We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice.** It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.* ### Valuation is complex, but we're here to simplify it. Discover if Zoetis might be undervalued or overvalued with our detailed analysis, featuring **fair value estimates, potential risks, dividends, insider trades, and its financial condition.** Access Free Analysis ### Related Stocks - [ZTS.US](https://longbridge.com/en/quote/ZTS.US.md) ## Related News & Research - [Zoetis declares Q3 2026 dividend of R$ 0.11 per unit](https://longbridge.com/en/news/297931039.md) - [Zoetis Inc. $ZTS Shares Acquired by Wealthfront Advisers LLC](https://longbridge.com/en/news/296596701.md) - [Zoetis CEO Peck, CFO Saccaro to speak at Morgan Stanley Global Healthcare Conference](https://longbridge.com/en/news/297777894.md) - [Zoetis' (ZTS) Market Perform Rating Reaffirmed at William Blair](https://longbridge.com/en/news/295128765.md) - [TD Cowen Sticks to Their Buy Rating for Zoetis (ZTS)](https://longbridge.com/en/news/296834705.md) --- > **Disclaimer: This article is for reference only and does not constitute any investment advice.**